Last updated: June 1, 2026
VIORELE (desogestrel/ethinyl estradiol): Who supplies it, and what’s behind the product’s supply chain
VIORELE is a combined oral contraceptive (COC) brand containing desogestrel (progestin) and ethinyl estradiol (estrogen). It is typically manufactured and supplied through a branded-generic style supply chain that combines (1) upstream API and formulation manufacturing, (2) finished-dose packaging and release sites, and (3) distribution channels into national markets.
No supplier-identifying data (manufacturers, packagers, API makers, labeler/distributors, or country-specific registrations) is provided in the prompt. Without those specifics, an accurate, supplier-level mapping cannot be produced.
Which companies supply VIORELE tablets in Europe and other markets?
Featured-snippet answer: Not determinable from the provided information.
What “suppliers” can mean for VIORELE
For pharmaceutical sourcing, “suppliers” can refer to:
- API supplier (desogestrel and ethinyl estradiol manufacturers)
- Finished-dose manufacturer (tablet core production, granulation/compression, coating)
- Packager (blister/carton packaging)
- Marketing authorization holder / labeler (the legal entity on the package and in the regulatory dossier)
- Local distributor (often different from the MAH in each country)
- Clinical or contract manufacturers supporting scale-up
None of these mappings can be tied to VIORELE without product-registration or labeler/manufacturer fields.
How can I identify the API and finished-dose manufacturers for VIORELE?
Featured-snippet answer: Not determinable from the provided information.
Typical identification routes
Accurate supplier identification normally relies on one or more of:
- Regulatory product monographs and SPC/SmPC manufacturer sections
- National drug registers listing MAH and manufacturing sites
- Label information on the blister/carton (manufacturer and packager addresses)
- Procurement or qualification documents for the specific strength and pack size
No such identifiers are included in the prompt.
What does the Orange Book status of VIORELE tell you about suppliers?
Featured-snippet answer: Not determinable from the provided information.
Orange Book limitation
The FDA Orange Book is U.S.-specific and only covers products approved via FDA pathways; it does not cover many non-U.S. brands. Without knowing whether VIORELE is listed in the Orange Book and under what applicant/labeler name, supplier conclusions cannot be drawn.
What patent estate controls VIORELE’s supply and contract manufacturing?
Featured-snippet answer: Not determinable from the provided information.
Why supplier mapping and patents intersect
In COCs, suppliers often use:
- bulk API supply agreements
- formulation process know-how
- packaging and regulatory-approval pathways
But a patent or exclusivity-linked supplier assessment requires:
- exact U.S./EU authorization details
- strength and dosage form
- application type and any reference product mapping
No such details are provided.
When do supplier contracts for VIORELE change due to exclusivity or manufacturing shifts?
Featured-snippet answer: Not determinable from the provided information.
What drives timing changes
Supplier changes usually follow:
- manufacturing site transfers
- lifecycle changes (strength/pack changes)
- regulatory re-approvals
- generic or biosimilar-like competitive entries
None of these timelines can be established without regulatory and product-history data.
Which generic or equivalent products compete with VIORELE and who supplies them?
Featured-snippet answer: Not determinable from the provided information.
COC interchangeability
VIORELE’s active combination is desogestrel/ethinyl estradiol. Multiple equivalents exist in many markets, but competitor brand naming and supplier lists are country-specific. Without the country for VIORELE distribution and the exact strength, a credible supplier comparison cannot be made.
Key Takeaways
- VIORELE is a desogestrel/ethinyl estradiol combined oral contraceptive.
- The prompt does not include the regulatory labeler, marketing authorization holder, manufacturing site, or API/finished-dose supplier identifiers required to name suppliers.
- Supplier-level sourcing cannot be produced without those product-specific fields.
FAQs
- Who is the marketing authorization holder (MAH) of VIORELE?
- Where are VIORELE tablets manufactured and packaged?
- Which companies supply desogestrel and ethinyl estradiol for VIORELE?
- Is VIORELE listed in the FDA Orange Book under the same brand name?
- What are the closest desogestrel/ethinyl estradiol equivalents to VIORELE in my country?
References
- No sources were provided in the prompt.
